All posts by imreal

Saisei Pharma plans clinical study of oral MAF in COVID-19 patients


our innate immunity can fight off pathogens without causing inflammation and associated respiratory deterioration

Saisei Pharma today announced plans to initiate an international clinical trial. The decision is based on published preclinical evidence, preliminary reports from independent studies and is supported by data of the safety and efficacy of oral MAF in conditions that require the involvement of macrophages as the front line defense in innate immunity. Prior studies have indicated that oral MAF can activate macrophage activity at least three-fold within a few minutes after application. This outstanding phenomenon could play an important role in deploying rapid innate immune response against SARS-CoV-2. The MAF induced phagocytosis enhances antigen processing and their presentation to effector lymphocytes, which is critical in forming the adequate adaptive immune response and synthesis specific antiviral antibodies [1-4]. Enhanced phagocytosis of SARS-CoV-2 viral particles and quicker effective innate and adaptive immune responses increase the probability of the abortive or shorter infection course. In addition to reduced viral load, MAF can downplay hyperactive proinflammatory response causing respiratory failure.

‘’The efficient innate immune response against SARS-CoV-2 is critical since there is no pre-existing immunity to exotic coronaviruses in humans who were not exposed to it earlier. The potent effect of Saisei Pharma MAF on phagocytosis is not accompanied by clinical or biochemical signs of inflammation when administered to humans. This means that our innate immunity can fight off pathogens without causing inflammation and associated respiratory deterioration” said immunologist Dr. Galyna Kutsyna, MD/PhD.

“Saisei Pharma is taking a number of steps to address the urgent need arising from the COVID-19 pandemic,” said Dr. Toshio Inui, MD, Head Global Drug Development and Chief Medical Officer. “The potential that oral MAF could lead to faster recovery for COVID-19 patients with fewer requiring intensive care and mechanical ventilation is encouraging and merits further investigation. While oral MAF is very safe, its safety and efficacy profile has not yet been established with regards to COVID-19.”

Given the global spread of the pandemic, and as plans for the study are being finalized, Saisei Pharma also has set up an international compassionate use program for eligible patients, subject to local approvals. In addition, steps are taken to manage the anticipated increase in COVID-19 related requests for oral MAF without interrupting access for patients taking oral MAF for its current indications. Saisei Pharma intends to join key industry partners against COVID-19 to complement the array of available therapy options. To support access, Saisei Pharma is committed to keeping stable prices for its range of products that may help in the treatment of COVID-19.

About Saisei Pharma oral MAF

Clinically active form of oral MAF is derived from enzyme-treated dairy products. MAF resulted from decades-long R&D activity by Saisei Pharma aimed at improving production technology and ensure the product’s higher activity and stability. The final goal is to make oral MAF available globally for conditions involving inadequate immune response due to macrophage dysfunction and hyper immune-inflammatory disorders in adult and pediatric patients. Saisei Pharma has filed a series of patents in Japan, EU, USA, and worldwide which relate to the technology, comprising the composition and method of production. Oral MAF is available as a health food or immunomodulating supplement in several countries, e.g., USA, Spain, Lithuania, and Ukraine. The exact indication for oral MAF varies by country. Additional worldwide regulatory filings are underway in other countries. Information about Saisei Pharma is available on the company website http://www.saisei-pharma.co.jp.

Saisei Pharma Global Media Relations

Contact: Mr. Martin Mette

Email: contact-sp@saisei-pharma.co.jp

Tel: +81-90-8823-0885

References

1. Sumiya Y, Ishikawa M, Inoue T, Inui T, Kuchiike D, Kubo K, Uto Y, Nishikata T. Macrophage activation mechanisms in human monocytic cell line-derived macrophages. Anticancer Res 2015;35:4447-51.

2. Ishikawa M, Mashiba R, Kawakatsu K, Tran NK, Nishikata T. (2018). A high-throughput quantitative assay system for macrophage phagocytic activity. Macrophage 2018;5:e1627.

3. Uto Y, Kawai T, Sasaki T, Hamada K, Yamada H, Kuchiike D, Kubo K, Inui T, Mette M, Tokunaga K, Hayakawa A, Go A, Oosaki T. Degalactosylated/desialylated bovine colostrum induces macrophage phagocytic activity independently of inflammatory cytokine production. Anticancer Res 2015;35:4487-92.

4. Mohamad SB, Hori H, Nagasawa H, Usui K, Uto Y. Characterization of human Gc protein-derived macrophage activation factor (GcMAF) and its functional role in macrophage tumoricidal activity. Adv Exp Med Biol. 2003;510:77‐82.

Disclaimer

This press release contains forward-looking statements regarding potential marketing approvals, new indications or labeling for oral MAF, regarding potential future revenues from such products, regarding our plans to initiate a clinical trial to evaluate the use of oral MAF in COVID-19 patients, or regarding the international compassionate use program for eligible patients. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There is no guarantee that oral MAF will be submitted or approved for sale or for any additional indications or labeling in any market, or at any predetermined time. Neither can there be any guarantee that we will initiate the planned clinical trial in the expected time frame. Nor can there be any guarantee that oral MAF will meet the primary or secondary endpoints of the planned trial. Neither can there be any guarantee that oral MAF will be commercially successful in the future. Our expectations regarding Saisei products and the international compassionate use program could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors. Saisei Pharma is providing the information in this press release as of this date and does not undertake any obligation to update forward-looking statements contained in this press release as a result of new information, future events or otherwise.

Share article on social media or email:

Opto 22 announces groov EPIC firmware version 2.0


Opto 22’s latest groov EPIC firmware adds support for groov RIO edge I/O

Today, Opto 22 announced the second major version of its firmware for groov EPIC®, the edge programmable industrial controller for automation applications and the industrial internet of things (IIoT). The groov EPIC 2.0 firmware includes updates to both of groov EPIC’s real-time control engines and provides an under-the-hood refresh to many ecosystem components. This update also increases the reach of the control platform with support for groov RIO®, Opto 22’s new industrial edge I/O module, which supports 61,260 unique I/O combinations in a standalone unit.

With groov EPIC 2.0, Opto 22’s PAC Control™, a flowchart-based, multi-tasking control engine, is updated to version R10.3a; and 3S Software’s CODESYS® Runtime, an IEC 61131-3 compliant runtime engine, is updated to version 3.5.15.10. Both control options are capable of executing user-configured, high-speed, closed-loop control programs for process control, manufacturing, and OEM machines. In combination with the jointly updated design software—PAC Project™ Suite 10.3 and Opto 22’s CODESYS Library Package 2.0.0.0, which is compatible with the CODESYS Development System v3.5 SP15—these updates allow the number of groov EPIC I/O points to be expanded with an unlimited number of groov RIO remote I/O modules. Each groov RIO module is an independent edge I/O unit that can sense and control a wide variety of traditional wired I/O signals or devices from anywhere on a connected Ethernet network.

groov RIO modules accept a software-configurable mix of analog inputs (volt, millivolt, milliamp), temperature inputs (ICTD, TC), discrete and powered switch inputs, analog outputs (volt, milliamp), discrete outputs, and normally-open or -closed relay outputs. Each module is also capable of executing up to four PID loops independently of the EPIC controller.

Direct interoperability between the groov EPIC system and the new groov RIO modules gives engineers, technicians, and developers more options for distributed and direct-to-cloud I/O processing. In addition to communicating I/O signals to the EPIC, each groov RIO module provides basic and advanced I/O signal processing, database transaction capability, and communications with other control systems, web services, and cloud IoT platforms, independently of groov EPIC. Both groov RIO and Opto 22’s field-proven SNAP I/O system are compatible remote I/O with the groov EPIC 2.0 firmware.

With groov EPIC 2.0 and groov RIO, applications like remote condition monitoring, building management systems (BMS), and data center infrastructure monitoring (DCIM)—applications that need to move many real-world signals into on-premises or cloud-based software—become easier than ever before, simplifying the complex technology stack and cross-functional skillset previously required for these applications.

The update rounds out this significant platform expansion with upgrades and improvements to many basic system components, providing better user management controls, more flexible serial device detection, and more stable VPN and MQTT performance. Third-party applications are also updated, including Ignition (7.9.13) and Node-RED (1.0.3). As a final note with this release, Opto 22 has added the popular, open-source Mosquitto™ to its cryptographically signed repository, providing users a proven, no-cost option for adding an MQTT broker to groov EPIC.

Availability

groov EPIC firmware 2.0 is available now for all current users through manage.groov.com. Complete upgrade instructions are available in the groov EPIC User’s Guide. For new customers, all groov EPICs now ship with this latest firmware version.

PAC Project Basic 10.3 and the Opto 22 Library Package for CODESYS 2.0.0.0 are also available as free downloads.

About groov EPIC

groov EPIC is an edge programmable industrial controller (EPIC). More than a PLC, PAC, or PC, it is a Linux®-based processor in a compact industrial enclosure, with local and remote I/O and wide-ranging programming and communications options. In addition to real-time control, groov EPIC provides the connectivity many of today’s projects require: it connects to field sensors and devices, legacy PLC systems, software applications, remote equipment, and cloud services for anything from weather conditions to big data analytics and predictive maintenance.

About Opto 22

Opto 22 designs and manufactures industrial control products and Internet of Things platforms that bridge the gap between information technology (IT) and operations technology (OT). Based on a core design philosophy of leveraging open, standards-based technology, Opto 22 products are deployed worldwide in industrial automation, process control, building automation, industrial refrigeration, remote monitoring, and data acquisition applications. Designed and manufactured in the U.S.A., Opto 22 products have a worldwide reputation for ease-of-use, innovation, quality, and reliability. For over 40 years OEMs, machine builders, automation end-users, and information technology and operations personnel have and continue to trust Opto 22 to deliver high-quality products with superior reliability. The company was founded in 1974 and is privately held in Temecula, California, U.S.A. Opto 22 products are available through a global network of distributors and system integrators. For more information, contact Opto 22 headquarters at +1-951-695-3000 or visit http://www.opto22.com. Follow us on Instagram, Twitter, Facebook, LinkedIn, YouTube.

Share article on social media or email:



FOUND! The Best Quality Drinking Water in the World


The Hallstein Octagon

The Hallstein Octagon

Hallstein Water is now available for home and office subscription delivery in 5-gallon bottles only, throughout Europe, the UK, and the United States. UNFILTERED. UNTREATED. UNCOMPROMISED.

With the global interest in anything that will assist in boosting immune systems, the world is looking at hydration and the power of high alkaline water. However, the worldwide market for drinking water is extremely competitive and driven by marketing buzzwords. The water market generally favors the producer and not the consumer. Most bottling companies and municipalities use questionable drinking water sources, and in most cases the end result is a chemical cocktail.

Frustration over the lack of information and dubious quality standards drove the Austrian-American Muhr Family, with the help of researchers and water experts, to define a list of parameters on what true drinking water quality means. Their research yielded 8 core parameters with 4 more important points. The 8 are: pH, Sodium, Dissolved Oxygen, Nitrate, Total Organic Carbon, Total Dissolved Solids, Calcium to Magnesium Ratio, and Exit Temperature. While the 4 additional parameters are: Well Depth, No Treatment, No Pumping, and Filled Cold.

Rather than creating another synthetic product, the Muhrs were looking for a completely natural source that could fulfill those ideal values. Using the core parameter list, they thought it had to exist in nature.

At its core, the benefits of a good drinking water should boost the immune system, aid in avoiding inflammation and assist in cleansing.

Armed with the list of essential criteria for good water quality, the Muhrs contracted a team of geologists and hydro- geologists including the renowned Mag. Wolfgang Gadermayr to scout locations around the world that had the necessary geological attributes to produce this water.

In October 2005, an aquifer was struck that fulfilled the essential criteria the family was looking for – Hallstein Water. The source is located in the Dachstein region of the Austrian Alps, a UNESCO protected area. What followed was a rigorous testing procedure to determine that the aquifer itself was 100% sustainable and the quality never changed regardless of season. After acquiring 57+ permits, a state-of-the-art bottling facility was constructed with a continuously precision-welded stainless steel piping system to make sure the quality filled is pristine.

Hallstein Water is now available for home and office subscription delivery in 5-gallon bottles only, throughout Europe, the UK, and the United States, with additional shipping options globally. http://www.hallsteinwater.com

The Hallstein Octagon

Working with a team of scientists and water experts, we established 8 core parameters for defining drinking water quality. Using their criteria we began testing a large number of waters in laboratories. The results were eye-opening, revealing that there wasn’t a single commercially available drinking water that met their criteria for “high quality”, except Hallstein.

What water are you currently drinking?

Ensure the water you’re drinking is of the highest quality. Check that it meets the 8 core parameters, in addition to the criteria below.

1. High pH Balance: 8.0–9.5

2. Low/No Sodium: (less than) 1 mg/l

3. High Naturally Dissolved Oxygen: (greater than) 10 mg/l

4. Low Nitrate Level: (less than) 3 mg/l

5. Low Total Organic Carbon: (less than) 0.15 mg/l

6. Moderate Total Dissolved Solids: 50–300 mg/l

7. Calcium / Magnesium Ratio: 2:1

8. Low Exit Temperature: (less than) 7C : 44F


  • From a Deep Artesian Well (below 100m)
  • No treatment of any kind
  • Filled Cold
  • Filled via Gravity

Delivery: Hallstein is delivered in 5 gallon (19 liters) Tritan BPA-free bottles, to keep your water fresh and uncompromised. We supply a small range of high quality dispensers that we recommend for the most convenient way to get your Hallstein from bottle to glass. Please visit our website for more information.

If you already have a dispenser, our bottles use a standard size cap fitting

Share article on social media or email:

Noodoe EV and EVCS Enter Strategic Partnership


Noodoe EV Charging Station

We are tremendously impressed with Noodoe’s relentless customer service focused approach and their technical and engineering expertise. Together we’ll be able to further ensure that the future is electric.

Noodoe EV, a global leader in electric vehicle (EV) charging technology, has formed a strategic partnership with Los Angeles based EV Charging Solutions (EVCS), best known for providing Golden State businesses with complete turnkey, scalable charging solutions. The partnership was announced by Noodoe EV CEO Jennifer Chang and EVCS CEO Gustavo Occhiuzzo. Both companies are working to provide California with advanced cloud-based EV charging stations to meet EV demand expected to triple in the next few years.

“What makes Noodoe EV different is Noodoe EV OS, an advanced cloud-based operating platform that fully automates 24/7 service delivery, payment processing, and energy cost reduction,” says Chang. “Partnering with EVCS is a tremendous milestone, a substantial boost to develop our charger network business stream. It positions Noodoe at the forefront of both EV charging technology and equipment.”

“We are incredibly excited to partner with Noodoe to be the exclusive Network Provider that powers EVCS’s growing number of publicly accessible EV Charging sites. We are tremendously impressed with Noodoe’s relentless customer service focused approach and their technical and engineering expertise. Together we’ll be able to further ensure that the future is electric,” says Occhiuzzo.

Last year, Noodoe debuted “Powered By Noodoe,” a global technology partnership program giving businesses everything needed to enter the EV charging market. “Many businesses want to enter the market and become a supplier, but face engineering/time to market challenges,” says Chang. “We did all the heavy lifting by providing business partners with three key advanced technologies: EV charging stations, EV software, and EV OS cloud technology. Noodoe’s program, in partnership with EVCS, puts businesses on the fast track to expansion. Our EV OS is flexible and future-proof, able to integrate additional features as new industry priorities or requirements arise.” Current industry-leading features of Noodoe EV OS include Universal Charging Service, Comprehensive Payment Processing, Central Management, Service Personal Access, Automated Diagnostics, and Operational Analytics.

About Noodoe EV:

Noodoe EV is on a mission to make the world greener by accelerating the world’s transition to electric transportation. In this quest, we produce well-designed EV charging infrastructure solutions that help construction, retail, hospitality industries, and public sectors be part of the global zero-emission revolution.

Through innovation, Noodoe empowers businesses to turn their parking lots into profitable charging stations. We enable hotels to become recharging sanctuaries that attract high-value patrons. The company also provides charging infrastructure, enabling governments and energy companies to build eco-friendly “smart cities.” Beyond automobiles, Noodoe’s endeavors extend to motorcycles; through innovation, we partner with global brands to bring the electric riding experience to consumers worldwide. Noodoe provides products and services used in 110 countries.

About EVCS:

EVCS was founded in 2018 by Green Commuter founder Gustavo Occhiuzzo and finance expert Ian Vishnevsky, two serial entrepreneurs and visionaries who saw the opportunity to provide California businesses with charging stations as the number of electric vehicles on the road continued to multiply. While Green Commuter pioneered eco-friendly mobility through its fleet of all-electric vanpool vehicles, Occhiuzzo and Vishnevsky were determined to encourage greater electric vehicle participation by California residents through a scalable statewide charging solution. EVCS set about developing a unique and industry-disrupting approach to mobility power – most notably employing a complete turnkey approach that utilizes both public and private grants, rebates and other financial incentives to reduce the downside while optimizing the upside for participating site owners. Thanks to the enormous popularity of this approach, EVCS has already expanded its footprint from its downtown Los Angeles headquarters to the rest of the state.

EVCS is a B Lab Certified Benefit Corporation.

Share article on social media or email:

Team of PhD Researchers Unveil AI-powered Platform to Open Source COVID-19 Vaccine Development


Epitopes derived from SARS-CoV-2 proteins are presented at the cell surface by MHC molecules. CD8 T cells then recognize these epitopes and become activated, and proceed to eliminate the virus infected cells.

Epitopes derived from SARS-CoV-2 proteins are presented at the cell surface by MHC molecules. CD8 T cells then recognize these epitopes and proceed to eliminate the virus-infected cells.

The hope is that the scientific community will be able to leverage the results on Epitopes.world to help prioritize ongoing experimental work towards developing effective vaccination strategies.

A team of machine learning, immunology, and bioinformatics researchers today unveiled Epitopes.world, an AI-powered, open source, interactive web platform to help accelerate vaccine development for COVID-19. Led by Tariq Daouda, PhD, who is currently a postdoctoral researcher at Harvard Medical School, the team behind epitopes.world consists of volunteers who have doctoral degrees in machine learning and immunobiology, as well as bioinformaticians and web developers.

The process to develop a vaccine is typically a very lengthy and costly process due to the number of virus-infected cells that need to be analyzed – which tend to be rare, fragile, and precious. While obtaining his doctorate degree at the Institute for Research in Immunology and Cancer at the Université de Montréal, Dr. Daouda developed an AI algorithm that can predict which parts of a virus are more likely to be exposed at the surface of infected cells, which are called epitopes. These predictions can be used by researchers to generate a significantly shorter list of potential targets to test in the creation of a vaccine — essentially reducing a process that typically takes weeks or months to hours.

Today, this neural network, called CAMAP, has been made available for any researcher to use on Epitopes.world. Along with generating predictions for potential vaccine targets, epitopes.world will also contain interactive visualizations that will allow researchers to plot their results and use them for further research. In the future, the site will continue to grow with more tools that allow researchers to dive deeper into the data.

“COVID-19 stresses the need to accelerate the design of vaccines and therapies to reduce the human and economic impact of global pandemics,” said Tariq Daouda, PhD, team lead of Epitopes.world. “People infected with COVID-19 tend to have a significant decrease in circulating immune cells during the acute infection phase, making it difficult to systematically isolate enough immune cells to study appropriately in a lab. Through the results now available on Epitopes.world, the team is utilizing open source technologies to connect machine learning to biomedicine to help accelerate learnings and findings. The hope is that the scientific community will be able to leverage these results to help prioritize ongoing experimental work towards developing effective vaccination strategies.”

Dr. Daouda and his team built epitopes.world using open source technologies, which allowed them to not only accelerate the development of the project, but also allow researchers who use the platform to more easily collaborate and share results with each other. They also have a public API, and the code is available in GitHub under an open-source license.

ArangoDB, the leading open source multi-model graph database, serves as the backend of the portal, storing over 182,000 epitopes and their metadata: approximately 39,000 from SARS-CoV-2, 39,000 from SARS-CoV-1, and 104,000 from normal human sequences for comparison. As an open source, multi-model database, ArangoDB gives epitopes.world a streamlined deployment stack with data access flexibility as the project evolves in the future.

Jörg Schad, PhD, is the Head of Engineering and Machine Learning at ArangoDB and a core member of the epitopes.world team, responsible for the cloud infrastructure and maintenance. In order to support the project, ArangoDB is providing free cloud resources in the form of its fully-managed cloud offering, ArangoDB Oasis.

“The current situation with the novel coronavirus pandemic requires the combined expertise from a wide range of experts and diverse backgrounds ,” said Jörg Schad, PhD, Head of Engineering and Machine Learning at ArangoDB. “We are thrilled to be able to collaborate and contribute our knowledge and platform for scalable and high-performance data, and especially graph, processing to this project.”

Learn more

About epitopes.world

Epitopes.world is made and maintained by a multidisciplinary team of researchers and developers who are committed to share science openly and develop innovative ways of instantly disseminating research results when timing is crucial. Learn more at epitopes.world.

About ArangoDB

One engine. One query language. Multiple data models. With more than 7 million downloads and over 9,000 stargazers on GitHub, ArangoDB is the leading open source multi-model graph database. It combines the power of graphs with JSON documents, a key-value store, and a full-text search engine, enabling developers to access and combine all of these data models with a single, elegant, declarative query language.

Simplifying complexity and increasing productivity is the mission of ArangoDB Inc., the company behind the project. Founded in 2014, ArangoDB Inc. is a privately-held company backed by Bow Capital and Target Partners. It is headquartered in San Francisco and Cologne, Germany with offices and employees around the world. Learn more at http://www.arangodb.com.

Share article on social media or email:

Trua Health & Wellness First to Bring Cliovana™ to Alaska


Julie Kane ARPN Certified Cliovana Practitioner

Julie Kane APRN, Trua Health & Wellness is first to bring Cliovana to Alaska.

A prominent leader in female health, Julie Kane is introducing Cliovana to the Anchorage market by adding this first-of-its-kind treatment to her practice, Trua Health & Wellness.

Truly satisfying sex is an important part of a woman’s overall physical and emotional well-being at any age, but many women aren’t feeling as much pleasure as they’d like. Cliovana is a simple, completely non-invasive way to increase women’s arousal levels and their orgasm frequency and intensity. Cliovana does not use lasers, scalpels or needles, so there are no dangerous side effects.

Julie Kane received her Masters of Science in 2017 and has spent years focusing on improving the lives of women with her innovative and results-driven procedures. Many women want to get more out of sex, but they want to do it in a way that respects their body. Cliovana is the perfect solution because it enhances arousal at the cellular level and causes your body to do more of what it does naturally: regenerate cells.

So how does Cliovana work? The body is always regenerating cells. Cliovana just stimulates the body to do more of that, specifically in the genitals, which can lead to an increase in women’s long-term sexual responsiveness. The technologies employed by Cliovana has been used worldwide for decades to help with a variety of health issues. The treatment is four 10-minute sessions over the course of two weeks. Because it is 100% non-invasive, there is zero downtime.

Learn more about Cliovana

https://cliovana.com

practitionerinfo@cliovana.com

1-833-818-2546

About Julie Kane and Trua Health & Wellness

Julie Kane, APRN has an extensive wellness background. She received her Bachelors in Nursing Science in 2013 at Chamberlain University and then her Masters of Science in Nursing in 2017. Julie started Trua Health & Wellness as a way to provide integrative therapies with lifestyle modification to revolutionize healthcare in Alaska. She enjoys working in the Alaska National Guard and competing in triathlons, biathlons and cycling.

Given her knowledge and passion for female sexuality, Julie is excited to offer industry-edge treatments like Cliovana to her patients.

Share article on social media or email:

UT Health San Antonio researchers study antibodies against coronavirus


“Once we know the footprints of the antibodies that give the best inhibitory effect, we can take that footprint, essentially, and make it into a vaccine.”– Evelien Bunnik, Ph.D., of the Long School of Medicine at UT Health San Antonio

As laboratories across the country rush to find answers for the novel coronavirus, The University of Texas Health Science Center at San Antonio (UT Health San Antonio) is bringing a unique combination of expertise to bear on the crisis. The goal is a precise and effective vaccine to prevent infection, said Robert Hromas, M.D., professor and dean of the university’s Long School of Medicine.

UT Health San Antonio is supporting multiple research projects in vaccine development. “We are working very fast to attack this problem, because until we have a vaccine and a therapy, this virus represents a huge threat to humanity,” Dr. Hromas said.

UT Health San Antonio has repurposed strategic teams in its research enterprise to focus on the problem, he said.

For example, a team from the Long School of Medicine is on a quest to isolate antibodies that neutralize the novel coronavirus.

“People who had the infection and recovered from it make specific antibodies,” said researcher Evelien Bunnik, Ph.D., assistant professor in the Department of Microbiology, Immunology & Molecular Genetics. “We will obtain samples from these individuals and study the antibodies.”

Goal is to lock cells against viral spread

The novel coronavirus, which in some individuals with weaker immune systems gives rise to the respiratory syndrome COVID-19, features spike proteins on its coat. The virus uses the spikes to force its way into surrounding cells.

“You can sort of see it as a lock and a key,” Dr. Bunnik said. “The spike protein is the key that needs to bind to the lock on the host cell. If you can prevent the key from going into the lock, you can prevent infection. That is what a neutralizing antibody does.”

The researchers are studying the antibodies’ chemical footprints – where the antibodies bind on the spike proteins – to learn which antibodies inhibit the virus and which do not.

“Once we know the footprints of the antibodies that give the best inhibitory effect, we can take that footprint, essentially, and make it into a vaccine,” Dr. Bunnik said.

UT Health San Antonio researchers are working with colleagues at the Texas Biomedical Research Institute, where biosafety level 3 and 4 labs enable scientists to work with live virus.

“We will test our vaccine candidates at Texas Biomed to see if they actually block the virus from infecting cells,” Dr. Hromas said.

“This is another example of the outstanding partnership between our institutions,” said Larry Schlesinger, M.D., president and CEO of Texas Biomed.

Unique mice will aid the cause

UT Health San Antonio collaborators include Paolo Casali, M.D., professor in the Department of Microbiology, Immunology & Molecular Genetics. Dr. Casali has created mice that have a full human immune system (H-Mice). He will immunize H-Mice mice with the COVID-19 virus spike protein and analyze what kind of antibodies the mice produce. The goal is to compare the antibodies that are observed in the humanized mice after infection with antibodies from the novel coronavirus survivors.

“We will test the immune response of the humanized mice to identify vaccine candidates,” Dr. Hromas said.

“Many people around the country are looking for vaccines, but they’re not doing it quite the way we are,” Dr. Hromas said. “Our niche is that we can track an infection in our humanized H-Mice and compare it to the immune response in humans. Then we can go back and test what we find in humans in the humanized mouse. No one else has that capability.”

The team’s expertise runs the gamut from basic scientists looking at single amino acids of the spike proteins of the coronavirus to clinicians who are expert in running clinical trials in humans, Dr. Hromas said. The UT Health San Antonio portion of the team includes immunologists such as Dr. Casali, cell biologists such as Dr. Bunnik, structural biologists such as Yogesh Gupta, Ph.D., and clinical trialists including Dr. Hromas, Jan Evans Patterson, M.D., and Thomas Patterson, M.D. The Texas Biomed portion of the group will be led by Luis Martinez-Sobrido, Ph.D., a virologist and assisted by a team of 30 COVID-19 investigators and staff.

# # #

The Long School of Medicine at The University of Texas Health Science Center at San Antonio is named for Texas philanthropists Joe R. and Teresa Lozano Long. The school is the largest educator of physicians in South Texas, many of whom remain in San Antonio and the region to practice medicine. The school teaches more than 900 students and trains 800 residents each year. As a beacon of multicultural sensitivity, the school annually exceeds the national medical school average of Hispanic students enrolled. The school’s clinical practice is the largest multidisciplinary medical group in South Texas with 850 physicians in more than 100 specialties. The school has a highly productive research enterprise where world leaders in Alzheimer’s disease, diabetes, cancer, aging, heart disease, kidney disease and many other fields are translating molecular discoveries into new therapies. The Long School of Medicine is home to a National Cancer Institute-designated cancer center known for prolific clinical trials and drug development programs, as well as a world-renowned center for aging and related diseases.

The University of Texas Health Science Center at San Antonio, also referred to as UT Health San Antonio, is one of the country’s leading health sciences universities and is designated as a Hispanic-Serving Institution by the U.S. Department of Education. With missions of teaching, research, patient care and community engagement, its schools of medicine, nursing, dentistry, health professions and graduate biomedical sciences have graduated more than 37,000 alumni who are leading change, advancing their fields, and renewing hope for patients and their families throughout South Texas and the world. To learn about the many ways “We make lives better®,” visit http://www.uthscsa.edu.

Stay connected with The University of Texas Health Science Center at San Antonio on Facebook, Twitter, LinkedIn, Instagram and YouTube.

Rescue Dog Wines Partners with Best Friends Animal Society


Rescue Dog Wines has pledged $25,000 as their minimum commitment to Best Friends to help their mission of ending the killing of dogs and cats in America’s shelters.

Just in time for National Pet Week, Rescue Dog Wines founders Blair and Laura Lott are announcing a partnership with national animal welfare organization Best Friends Animal Society.

Rescue Dog Wines has pledged $25,000 as their minimum commitment to Best Friends to help their mission of ending the killing of dogs and cats in America’s shelters.

“Best Friends’ mission aligns perfectly with our goals,” explains Blair Lott. “Rescue Dog Wines gives away half of our profits to support dog rescue programs, and now with the reach of Best Friends, we’ll be able to be even more effective, he added.

“Best Friends is delighted to launch this collaboration,” Eric Rayvid, public relations director, Best Friends Animal Society. “We know we won’t be able to achieve our mission without critical funds from partners like Rescue Dog Wines.

The first element of the collaboration is special pricing that Rescue Dog Wines is offering to customers who learn about the winery through Best Friends. When buying wines on the website, purchasers can use “BESTFRIENDS2020” code and that will generate a promotional price of a 10% discount and a donation of 10% of the purchase price to Best Friends.

All of Rescue Dog’s wines are sourced from the Lodi, California appellation; the grape growing and winemaking follow “Lodi Rules,” a set of guidelines oriented to sensitive farming and superlative wine quality. The winery’s current releases are 2018 Rosé, Beloved Mixed Red Wine Blend (NV), Predominantly Poodle Sauvignon Blanc (NV), Bubbly Boxer Sparkling Rosé (NV) and Bubbly Boxer Demi-Sec Sparkling Wine (NV). The wines can be purchased from the winery’s website and are also in limited distribution in some cities in the U.S.

Rescue Dog Wines was founded in 2017 by Blair and Laura Lott. The Lotts participate in events like National Dog Day; last year the winery did a joint program with Hotel Milo in Santa Barbara, California, where dogs were welcomed with treats and gifts, and owners with choices of the Rescue Dog wines. “This type of collaborative effort brings us great joy,” comment Blair and Laura Lott, who have participated in similar events including the Sacramento SPCA Fall Gala, Friends of the Alameda (California) Animal Shelter, the Lodi PALS (People Assisting Lodi Shelter), Los Angeles Found Animals Foundation, The Rescue Dog Runway Show in Los Angeles and the English Bulldog Rescue Bully Ball in Atlanta.

National Pet Week, organized by the American Veterinary Medical Association, takes place May 3-9, 2020. It celebrates the pets that enrich our lives and encourages responsible pet care every day of the year. Created by the AVMA and the Auxiliary to the AVMA in 1981, it’s observed during the first full week of May each year. More: https://www.avma.org/events/national-pet-week

Share article on social media or email:

Solay Mobile App Provides Social Distancing Technology for Resort Pools & Beaches


Paradise Reserved with a tap, not your towel.

Resort Technologies, LLC, proudly announces the iOS initial release of its mobile technology solution, Solay, available now for download in the App Store. The Solay Mobile App provides Resorts & Hotels with a free inventory management system to set up overnight guests with reserved seats placed 6 feet apart at pools and beaches. Offering a contactless solution to maintain social distancing, Resorts & Hotels utilizing Solay contribute to a safer return to travel and experience greater ease in adhering to COVID-19 guidelines.

The Solay Mobile App is a seating reservation tool used by overnight guests that generates real time information to Hotels & Resorts. Solay utilizes customized property information and seating maps, organizing the logistics of social distancing among Hotel & Resort registered guests when they enjoy pools and beaches. Solay has a no contact reservation and check-in process on each user’s individual iPhone and does not require any other integrations or property technology solutions. As an effective way to manage vacation experiences through the challenges of COVID-19, the Solay service will promote reassurance and increase confidence of guests vacationing at Hotels & Resorts. Resort & Hotel Management staff can re-open with peace of mind knowing Solay provides a cost-free system to support property and guest needs alike at pools and beaches without the uncertainty of a first come, first served model.

Solay is also proud to announce all user fees are currently waived to help support hospitality and encourage vacationers to enjoy leisure time again. The Solay Mobile App was established to allow the pure essence of the word “vacation” to be embodied in the guest experience. Solay, a better experience for all.

Solay is now available for free download in the iOS App Store. Android is planned for release in Q1 of 2021 along with development of additional features. More information can be found online at http://www.solayapp.com.

About Resort Technologies, LLC

Resort Technologies, LLC, is a San Diego-based technology firm founded in 2019 to develop innovative technology solutions in the hospitality space. Most notably, the company focuses on addressing inefficiencies in the market of resort guest experiences. With the launch of their first product, the solayTM app, resort guests can effortlessly make advance reservations of poolside and beach lounge chairs and cabanas at resorts, completely avoiding the hassle of unreserved seating. In keeping with its mission to enhance the guest experience, Resort Technologies gives a portion of every reservation back to nonprofits engaged in environmental conservation and ocean restoration. The company will be announcing new features to the solayTM app along with continued development plans for hospitality technology solutions in the future. Sleep in, your seat is set.

Share article on social media or email:

HealthTalk A.I. Adds Telehealth Service to its Patient Outreach Platform


HealthTalk A.I. Logo

HealthTalk A.I.

This capability is giving them what they need to deliver safe, easy and scalable virtual care experiences.

HealthTalk A.I., a leading patient relationship and outreach technology company, today announced the addition of telehealth capabilities to its list of AI-driven solutions. This enhancement will enable its customers to easily schedule and initiate HIPAA secure virtual interactions with their patients.

The COVID-19 crisis continues to illustrate the importance of human distancing and telehealth’s role in preventing potentially dangerous encounters. “We’re very excited about our new telehealth functionality and how it’s already helping our provider customers,” said Jerrod Ullah, founder & CEO of HealthTalk A.I. “They’re the ones on the front line and this capability is giving them what they need to deliver safe, easy and scalable virtual care experiences.”

“Our emergency care has drastically changed with COVID-19. Now, more than ever, there is a real clinical need to follow up with patients showing COVID-19 symptoms,” said Dr. Bahareh Aslani, MD, Medical Director at Inova Fairfax Emergency Department. “Healthtalk A.I. has helped us for more than a year with scheduling physician follow up based on experience or quality issues post discharge. They are now helping us automate, schedule and deliver telehealth. This is something we could not do before and they’ve made it exceptionally easy to use!”

Cassie Lindholm, MPA, PCMH CCE, Director of Quality at Upper Great Lakes Family Health Center, pointed out that HealthTalk A.I. has been instrumental in helping them care for their community virtually. “We’ve been able to automate COVID-19 symptom triage for our entire patient population, schedule patients for phone call visits, and connect patients to our drive-through testing site. We’ve also been using HealthTalk to assess patients’ behavioral health and community resource needs and connect them with support. We’re looking forward to using the new telehealth capability to further our virtual care efforts,” she said.

About HealthTalk A.I.:

HealthTalk A.I. is a patient relationship and outreach platform built to help healthcare providers maximize patient communication, improve follow-up care and gain insight into patient experience at scale. Its fully-automated, text-based system delivers user-friendly communication with specific messages and rules dictated by each healthcare organization. It gives providers the ability to engage 100% of their population and close the loop with telehealth services — further decreasing risk and amplifying quality of care impact. To learn more about HealthTalk A.I.’s solutions, please visit HealthTalkAI.com.

Share article on social media or email: